SLC5A2 and type 2 diabetes mellitus: Although there are number of anti-diabetic therapies such as the sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists that have been shown to improve cardiovascular outcomes in people with type 2 diabetes [5], there are currently no approved therapies for the specific treatment of DbCM.